Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560601 | 1.00 | NR1H4 (0.33) | NR1H4MAP4K4HDAC1HDAC2MAPKAPK2 | |
| SCHEMBL17560478 | 0.85 | HTR6 (0.36) | NR1H4MAP4K4MAPKAPK2 | |
| SCHEMBL17570145 | 0.85 | HTR6 (0.36) | NR1H4MAP4K4MAPKAPK2 | |
| SCHEMBL19426643 | 0.85 | KDM4E (0.39) | MAPKAPK2 | |
| SCHEMBL17560477 | 0.85 | HTR6 (0.36) | NR1H4MAP4K4MAPKAPK2 | |
| SCHEMBL19271241 | 0.83 | HDAC1 (0.31) | MAP4K4HDAC1HDAC2 | |
| SCHEMBL19275814 | 0.82 | ALDH1A1 (0.47) | MAP4K4HDAC1HDAC2CA1CA2 | |
| SCHEMBL17569733 | 0.82 | ALDH1A1 (0.47) | MAP4K4HDAC1HDAC2CA1CA2 | |
| SCHEMBL16355923 | 0.82 | MEN1 (0.44) | — | |
| SCHEMBL17560485 | 0.82 | MAPT (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944641-B2 | Isoquinolinone derivatives useful in the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2018-04-17 | — | — | US | disclosed |
| US-9944641-B2 | Isoquinolinone derivatives useful in the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2018-04-17 | — | — | US | disclosed |
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-08-24 | — | — | US | disclosed |
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-08-24 | — | — | US | disclosed |
| EP-3189051-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Pierre Fabre Médicament (FR) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034642-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | TP53, KRAS, AQP1 | NR1H4 1187/4885MAP4K4 1440/4885HDAC1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.